無料プレビュー

Aclaris Therapeutics, Inc. (ACRS) · NASDAQ Global Select

プロフィール

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule kinase inhibitors and monoclonal antibodies for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. Key programs include bosakitug (anti-TSLP monoclonal antibody), ATI-2138 (ITK/JAK3 dual inhibitor), and ATI-052 (anti-TSLP/anti-IL-4Ra bispecific), targeting atopic dermatitis and asthma. The company pursues an out-licensing model, partnering with third parties for development, regulatory approval, and commercialization while relying on contract manufacturers for prod

主要指標

株価: $3.79 (+11.47%)
時価総額: 5億ドル
PER（今期予想）: -5.7
PBR: 4.3
配当利回り: —
52週レンジ: $1.74 – $6.60
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-05 · 更新: 2026-10-09